ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central ...

With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with a transaction set to propel the company into the CDMO market. Jabil on ...

NLS Pharmaceutics (NLSP) and Kadimastem announced that they have entered into a definitive merger agreement to combine the two companies to focus on advancing NLS’ promising, first-in class Dual ...

ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. NLS Pharmaceutics ( (NLSP)) just unveiled ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. NLS Pharmaceutics ( (NLSP)) has shared an ...

Chemistry is at the centre of our existence and offers transformative solutions to many global challenges, including health. RSC Pharmaceutics acknowledges how chemistry and related disciplines can ...

ZÜRICH, SWITZERLAND / ACCESSWIRE / July 3, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery ...

NewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and Plan of Reorganization, as amended from time to time, ...

Mark Egerton, PhD, chief executive officer of Quotient Sciences, shares insights on a new approach to accelerate drug development, which integrates formulation development, real-time adaptive GMP ...

NLS Pharmaceutics (NASDAQ:NLSP) rose in premarket trading on Monday after the company reported a definitive merger agreement with Kadimastem. NLSP (NLSP) stock climbed +57.22% to $5.66 +2.06 premarket ...